Predictive Oncology (POAI) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 12, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	1,446,159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		13,398,339
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and Cash Equivalents	$ 1,004,269	$ 766,189
Certificates of Deposit		244,971
Accounts Receivable	315,327	137,499
Notes Receivable	167,512	667,512
Inventories	244,660	265,045
Prepaid Expense and other assets	275,476	289,966
Total Current Assets	2,007,244	2,371,182
Notes Receivable	1,112,524	1,070,000
Equity Method Investment	581,742
Fixed Assets, net	184,385	87,716
Intangibles, net	115,139	95,356
Total Assets	4,001,034	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	165,588	140,462
Accrued Expenses	455,326	785,215
Deferred Revenue	18,342	6,663
Total Liabilities	639,256	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 12,089,446 and 6,943,283 outstanding	120,893	69,432
Additional paid-in capital	(62,138,569)	(57,380,256)
Accumulated Deficit	58,898,477	54,765,045
Total Stockholders' Equity	3,361,778	2,691,914
Total Liabilities and Stockholders' Equity	4,001,034	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		$ 6,479

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	12,089,446	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 358,586	$ 106,822	$ 770,179	$ 281,988
Cost of goods sold	108,970	22,010	226,314	59,003
Gross margin	249,616	84,812	543,865	222,985
General and administrative expense	729,528	2,214,705	1,945,670	3,346,777
Operations expense	378,906	182,507	666,496	383,001
Sales and marketing expense	554,084	231,270	1,104,623	378,724
Total Expense	1,662,518	2,628,482	3,716,789	4,108,502
Loss on equity method investment	(960,508)		(960,508)
Net loss attributable to common shareholders	(2,373,410)	(2,543,670)	(4,133,432)	(3,885,517)
Comprehensive loss	$ (2,373,410)	$ (2,543,670)	$ (4,133,432)	$ (3,885,517)
Loss per common share - basic and diluted (in dollars per share)	$ (0.20)	$ (0.41)	$ (0.36)	$ (0.62)
Weighted average shares used in computation - basic and diluted (in shares)	11,878,490	6,167,689	11,632,221	6,308,554

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Over-Allotment Option [Member]Preferred Stock [Member]	Over-Allotment Option [Member]Common Stock [Member]	Over-Allotment Option [Member]Additional Paid-in Capital [Member]	Over-Allotment Option [Member]Retained Earnings [Member]	Over-Allotment Option [Member]AOCI Attributable to Parent [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement One [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consulting Agreement One [Member]Preferred Stock [Member]	Consulting Agreement One [Member]Common Stock [Member]	Consulting Agreement One [Member]Additional Paid-in Capital [Member]	Consulting Agreement One [Member]Retained Earnings [Member]	Consulting Agreement One [Member]AOCI Attributable to Parent [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consulting Agreement Two [Member]Preferred Stock [Member]	Consulting Agreement Two [Member]Common Stock [Member]	Consulting Agreement Two [Member]Retained Earnings [Member]	Consulting Agreement Two [Member]AOCI Attributable to Parent [Member]	Consulting Agreement Two [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Helomics Holding Corp. [Member]Preferred Stock [Member]	Helomics Holding Corp. [Member]Common Stock [Member]	Helomics Holding Corp. [Member]Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]Retained Earnings [Member]	Helomics Holding Corp. [Member]AOCI Attributable to Parent [Member]	Helomics Holding Corp. [Member]	Investor Relations Consultant [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Investor Relations Consultant [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Investor Relations Consultant [Member]Preferred Stock [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]Retained Earnings [Member]	Investor Relations Consultant [Member]AOCI Attributable to Parent [Member]	Investor Relations Consultant [Member]	Series E Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]	Series E Warrants [Member]Common Stock [Member]	Series E Warrants [Member]Additional Paid-in Capital [Member]	Series E Warrants [Member]Retained Earnings [Member]	Series E Warrants [Member]AOCI Attributable to Parent [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Re-priced Warrants [Member]Preferred Stock [Member]	Re-priced Warrants [Member]Common Stock [Member]	Re-priced Warrants [Member]Additional Paid-in Capital [Member]	Re-priced Warrants [Member]Retained Earnings [Member]	Re-priced Warrants [Member]AOCI Attributable to Parent [Member]	Re-priced Warrants [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2016																																																										$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Balance (in shares) at Dec. 31, 2016																																																									79,246		4,564,428
Shares issued pursuant to the public offering				$ 1,750	$ 392,000			$ 393,750																																																			$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)				175,000																																																							1,750,000
Vesting Expense																																																												2,131,821			2,131,821
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																																											$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																																											(400,000)
Shares issued for services												$ 1,000	$ 219,000			$ 220,000																		$ 792	$ 61,894	$ 54,040,705	$ (50,903,968)		$ 3,199,423
Shares issued for services (in shares)												100,000																					79,246		6,189,428
Unrealized (loss) from marketable securities																																																														(1,501)	(1,501)
Net loss																					$ (3,885,517)		$ (3,885,517)
Net loss																					$ (3,885,517)		$ (3,885,517)
Balance at 1/1/2018 at Dec. 31, 2017																																																										7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance at 1/1/2018 (in shares) at Dec. 31, 2017																																																								647,819	79,246		6,943,283
Shares issued pursuant to the public offering				$ 2,153	$ 202,268	$ 1		$ 204,422																																																			$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)				215,247																																																							2,900,000
Vesting Expense																																																												460,368			460,368
Net loss																																																													(4,133,432)		(4,133,432)
Preferred conversion to common shares pursuant to private placement agreement																																																										(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																								(647,819)			589,747
Investment pursuant to Helomics 20% acquisition																											$ 11,000	$ 1,031,250			$ 1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)																											1,100,000
Warrant exercises																																											$ 888	$ 87,948			$ 88,836				$ 2,523	$ 249,810			$ 252,333
Warrant exercises (in shares)																																											88,836								252,333
Net loss																																																													(4,133,432)		(4,133,432)
Balance at 1/1/2018 at Jun. 30, 2018																																																										$ 792	$ 120,893	$ 62,138,569	$ (58,898,476)		$ 3,361,778
Balance at 1/1/2018 (in shares) at Jun. 30, 2018																																																									79,246		12,089,446

Statement of Stockholders' Equ6

Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Jun. 30, 2018$ / shares
Series E Warrants [Member] | Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Common Stock [Member] | Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	0.9497
Warrant exercises, exercise price per share (in dollars per share)

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities:
Net loss	$ (4,133,432)	$ (3,885,517)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	960,508
Depreciation and amortization	41,062	35,995
Vested stock options and warrants	460,368	2,131,821
Equity instruments issued for management and consulting		216,000
Loss from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(177,828)	(6,085)
Inventories	20,385	30,004
Prepaid expense and other assets	14,490	(39,892)
Accounts payable	25,126	(162,685)
Accrued expenses	(329,889)	(394,767)
Deferred revenue	11,679	6,159
Net cash used in operating activities:	(3,107,531)	(2,070,804)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,593,174)
Redemption of certificates of deposit	244,971
Advance on notes receivable	(42,524)
Purchase of fixed assets	(129,990)	(38,637)
Purchase of intangibles	(27,524)	(1,229)
Net cash provided by (used in) investing activities:	44,933	(2,348,375)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	341,169
Issuance of common stock	2,959,509	3,814,938
Net cash provided by financing activities	3,300,678	3,814,938
Net increase (decrease) in cash and cash equivalents	238,080	(604,241)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	1,004,269	1,159,849
Non-cash transactions:
Conversion of Preferred Stock to Common Stock	6,479
Equity method investment - Helomics	$ 1,542,250

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of June 30, 2018, 12,089,446 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $58,898,477. not $1,004,269 June 30, 2018 one not Since inception to June 30, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first June 30, December 31, Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: June 30, December 31, Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $18,825 $33,321 three six June 30, 2018 $14,519 $30,204 three six June 30, 2017. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $4,070 $7,741 three six June 30, 2018 $2,902 $5,790 three six June 30, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $794,125 Segments The Company operates in two three six June 30, 2018 2017 $3,178 $0 three 2018 2017, $5,866 $26,662 first six 2018 2017, Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 2 Equity Method Investment

Note 2 Equity Method Investment	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 2 The Company has an equity method investment in Helomics. The unaudited six Helomics Holdings Corporation For the Six Months Ended June 30, 2018 Revenue $ 118,697 Gross margin $ (25,539 ) Net loss from continuing operations $ (4,285,054 ) Net loss to investee $ (3,324,546 ) 1 1 80% January 11, 2018 – February 27, 2018, 75% six Helomics’ first six not $1.2M one

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2018, December 31, 2017, $315,327 $137,499, For the three six June 30, 2018, not The Company deferred revenues related primarily to maintenance plans of $18,342 $6,663 June 30, 2018 December 31, 2017, Practical Expedients The Company has elected the practical expedient not

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Merger Agreement with Helomics On June 28, 2018, not 7.5 1.1 20% 860,000 18 $7.6 18.7 $1.00 5.0 $1.00 75% $7.6 0.6 $1.00 23.7 14.2 $1.00 995,000 $0.01 597,000 $0.01 Completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics. Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 3.00% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97 At June 30, 2018, 2,154,442 $2.05 9.40 2,556,382 six June 2018 June 2017 $460,368 18,276 $997,772 16 The following summarizes the status of options and warrants outstanding at June 30, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of June 30, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 – 2.10 2018 482,402 0.91 – 1.35 Total 3,120,255 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 – 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38

Note 5 - Notes Receivable

Note 5 - Notes Receivable	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, 8% two February 28, 2020. In October 2017, $600,000 December 2017, $67,512 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512

Note 6 - Loss Per Share

Note 6 - Loss Per Share	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 6 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 ) ( 1 June 30, 2018 June 30, 2017 5,676,637 3,850,878, June 30, 2018 79,246.

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 7 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012

Note 8 - Subsequent Events

Note 8 - Subsequent Events	6 Months Ended
	Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 8 On July 13, 2017, 2012 2016 July 28, 2016, not December 2017, July 2018, no

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of June 30, 2018, 12,089,446 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $58,898,477. not $1,004,269 June 30, 2018 one not Since inception to June 30, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first June 30, December 31, Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: June 30, December 31, Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $18,825 $33,321 three six June 30, 2018 $14,519 $30,204 three six June 30, 2017.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $4,070 $7,741 three six June 30, 2018 $2,902 $5,790 three six June 30, 2017.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $794,125
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in two three six June 30, 2018 2017 $3,178 $0 three 2018 2017, $5,866 $26,662 first six 2018 2017,
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 1 - Summary of Significa17

Note 1 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3
Property, Plant and Equipment [Table Text Block]	June 30, December 31, Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716

Note 2 Equity Method Investme18

Note 2 Equity Method Investment (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Equity Method Investments [Table Text Block]	Helomics Holdings Corporation For the Six Months Ended June 30, 2018 Revenue $ 118,697 Gross margin $ (25,539 ) Net loss from continuing operations $ (4,285,054 ) Net loss to investee $ (3,324,546 ) 1

Note 4 - Stockholders' Equity19

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 – 2.10 2018 482,402 0.91 – 1.35 Total 3,120,255 $0.91 – $596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 – 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38

Note 6 - Loss Per Share (Tables

Note 6 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 )

Note 1 - Summary of Significa21

Note 1 - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	196 Months Ended
	Jan. 31, 2018USD ($)	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018	Feb. 21, 2018$ / shares	Dec. 28, 2017$ / shares	Dec. 31, 2016USD ($)
Common Stock, Shares, Outstanding, Ending Balance | shares		12,089,446		12,089,446		6,943,283	12,089,446
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01		$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance		$ (58,898,477)		$ (58,898,477)		$ (54,765,045)	$ (58,898,477)
Cash and Cash Equivalents, at Carrying Value, Ending Balance		1,004,269	$ 1,159,849	1,004,269	$ 1,159,849	766,189	1,004,269				$ 1,764,090
Stockholders' Equity, Period Increase (Decrease), Total							35,840,380
Stock Issued During Period, Value, New Issues				2,755,087		3,421,188
Debt Instrument, Increase (Decrease), Net, Total							$ 5,685,000
Depreciation, Total		18,825	14,519	33,321	30,204
Amortization of Intangible Assets, Total		4,070	2,902	7,741	5,790
Income Tax Expense (Benefit), Total		$ 0	0	$ 0	0
Valuation Allowance Percentage		100.00%		100.00%			100.00%
Unrecognized Tax Benefits, Ending Balance		$ 0		$ 0			$ 0
Cash, Uninsured Amount		794,125		$ 794,125			794,125
Number of Operating Segments				2
Non-US [Member]
Revenues, Total		$ 3,178	$ 0	$ 5,866	$ 26,662
Earliest Tax Year [Member]
Open Tax Year				2,014
IPO [Member]
Stock Issued During Period, Value, New Issues							13,555,003
Proceeds from Issuance or Sale of Equity, Total							3,937,500
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs							1,739,770
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues				$ 204,422		$ 393,750
Proceeds from Issuance or Sale of Equity, Total							358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 2,755,000						2,755,000
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues							2,055,000
Series C Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues							$ 1,300,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest								25.00%

Note 1 - Summary of Significa22

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Finished goods	$ 31,782	$ 62,932
Raw materials	168,735	141,028
Work-In-Process	44,143	61,085
Total	$ 244,660	$ 265,045

Note 1 - Summary of Significa23

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	6 Months Ended
	Jun. 30, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa24

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 491,476	$ 361,486
Less: Accumulated depreciation	307,091	273,770
Total Fixed Assets, Net	184,385	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	201,123	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	122,188	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 59,210	$ 43,368

Note 2 Equity Method Investme25

Note 2 Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	80.00%
Debt Conversion, One-time Expense	$ 1.2

Note 2 - Equity Method Investme

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) - Helomics Holding Corp. [Member]	6 Months Ended
	Jun. 30, 2018USD ($)
Revenue	$ 118,697
Gross margin	(25,539)
Net loss from continuing operations	(4,285,054)
Net loss to investee	$ (3,324,546)	[1]
[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the six-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 315,327	$ 137,499
Contract with Customer, Liability, Current	$ 18,342	$ 6,663
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity28

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)	Jun. 28, 2018USD ($)$ / sharesshares	Mar. 12, 2018$ / sharesshares	Feb. 21, 2018USD ($)$ / sharesshares	Jan. 15, 2018$ / sharesshares	Jan. 11, 2018USD ($)shares	Jan. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Dec. 31, 2017$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)shares	Jan. 02, 2018shares	Dec. 28, 2017$ / sharesshares	Jan. 29, 2017shares	Oct. 27, 2016shares
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01			$ 0.01
Common Stock, Shares Authorized							50,000,000	50,000,000		50,000,000	50,000,000			50,000,000	24,000,000	8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number								2,154,442			2,154,442
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares								$ 2.05			$ 2.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term								9 years 146 days
Class of Warrant or Right Number of Warrants Vested and Exercisable								2,556,382			2,556,382
Allocated Share-based Compensation Expense, Total | $								$ 460,368	$ 18,276
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $								$ 997,772			$ 997,772
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $							$ 1,900,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								482,402		2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares								$ 1.11		$ 1.45
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 120 days
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 0.97
Number of Equal Installments Options are Expected to Vest				4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares		$ 1.35
Number of Equal Installments Options are Expected to Vest		4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 609.38			$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares								$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								3.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares								$ 1.0044
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								0			$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares								$ 0.91
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								2.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term								5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares								$ 0.4816
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													5,000,000
Helomics Holding Corp. [Member]
Notes Payable, Total | $	$ 7,600,000
Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues					1,100,000
Share Exchange Agreement, Shares Received					2,500,000
Share Exchange Agreement, Convertible Notes Receivable | $												$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock												5.00%
Share Exchange Agreement, Potential Interest												25.00%
Share Exchange Agreement, Number of Shares Held in Escrow												1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum | $					$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent					20.00%
Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price | $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] | Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues						2,900,000
Share Price | $ / shares						$ 0.95
Proceeds from Issuance or Sale of Equity, Total | $						$ 2,755,000					$ 2,755,000
The 2018 Public Offering [Member] | Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit						0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues			215,247
Proceeds from Issuance or Sale of Equity, Total | $											$ 358,312
Sale of Stock, Underwriter Option Term						45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase						290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase						87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares						$ 0.001
Shares Issued, Price Per Share | $ / shares			$ 0.9497
Proceeds from Underwriter Shares Exercised, Net | $			$ 188,066
Stock Issued During Period, Underwriter Discount | $			$ 16,354
Underwriter Discount Percentage			8.00%

Note 4 - Stockholders' Equity29

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,120,255
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22
Number of Shares Issued (in shares)	957,000	1,082,946
Average Exercise Price Issued (in dollars per share)	$ 1	$ 1.49
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(341,169)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	2,556,382	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 5.97	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	482,402	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.11	$ 1.45
Number of Shares Expired (in shares)	(127,130)	(12,730)
Average Exercise Price Expired (in dollars per share)	$ 2.22	$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	3,120,255	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.85	$ 2

Note 3 - Stockholders' Equity,

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Shares, options (in shares)	3,120,255
Warrant exercises, exercise price per share (in dollars per share) | $ / shares
Shares, warrants (in shares)	2,556,382
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 1
Shares, warrants (in shares)	1,372,828
Weighted average remaining life, warrants (Year)	4 years 131 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	4 years 127 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 208 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	2 years 62 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	1 year 40 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	1 year 131 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	229 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share) | $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	219 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.91
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 292 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.965
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 321 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 189 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.01
Shares, options (in shares)	124,358
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.10
Shares, options (in shares)	22,730
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.13
Shares, options (in shares)	143,807
Weighted average remaining life, options (Year)	10 years
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 259 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	9 years 94 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.47
Shares, options (in shares)	2,373,226
Weighted average remaining life, options (Year)	8 years 361 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 277 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	8 years 58 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.42
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	8 years 51 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 3.75
Shares, options (in shares)	3,998
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	8 years 94 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	8 years 80 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	8 years 69 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	7 years 116 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	7 years 94 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	4 years 69 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 262 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	4 years 47 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 94 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 14 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	5 years 14 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 200 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 313 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 251 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 186 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years 91 days

Note 4 - Stockholders' Equity31

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Shares, options (in shares) | shares	3,120,255
Shares, warrants (in shares) | shares	2,556,382
Warrant exercises, exercise price per share (in dollars per share)
Minimum [Member]
Price, options (in dollars per share)	0.91
Warrant exercises, exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares) | shares	6,455
Warrants 2014 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) | shares	94,151
Warrants 2015 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) | shares	504,666
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) | shares	1,082,946
Warrants 2017 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) | shares	868,164
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2018 [Member] | Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)
Warrants 2018 [Member] | Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)
Stock Options 2011 [Member]
Shares, options (in shares) | shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) | shares	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) | shares	1,553
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) | shares	836
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) | shares	4,088
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) | shares	100,292
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) | shares	2,529,070
Stock Options 2017 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) | shares	482,402
Stock Options 2018 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 0.91
Stock Options 2018 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Oct. 31, 2017	Jul. 31, 2017
Advance to Helomics [Member]
Payments to Acquire Notes Receivable			$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable		$ 67,512
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage	8.00%			8.00%
Financing Receivable, Net, Total	$ 1,112,524	$ 1,070,000
Notes Receivable, Term	2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total	$ 167,512
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock	5.00%
Investment, Ownership Percent	25.00%

Note 6 - Loss Per Share (Detail

Note 6 - Loss Per Share (Details Textual) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,676,637	3,850,878
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 6 - Loss Per Share - Share

Note 6 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss available in basic and diluted calculation		$ (2,373,410)	$ (2,543,670)	$ (4,133,432)	$ (3,885,517)
Weighted average common shares outstanding-basic (in shares)		11,878,490	6,167,689	11,632,221	6,308,554
Effect of diluted stock options, warrants and preferred stock (1) (in shares)	[1]
Loss per common share - basic and diluted (in dollars per share)		$ (0.20)	$ (0.41)	$ (0.36)	$ (0.62)
[1]	The number of shares underlying options and warrants outstanding as of June 30, 2018 and June 30, 2017 are 5,693,808 and 3,850,878, respectively. The number of shares underlying the preferred stock as of June 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 7 - Related Party Transa35

Note 7 - Related Party Transactions (Details Textual) - Director [Member]	1 Months Ended
	Apr. 30, 2018USD ($)shares
Related Party Transaction, Monthly Cash Payment | $	$ 12,000
Restricted Stock Units (RSUs) [Member] | Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares	240,000